TMCnet News

Dimension Therapeutics Elects Dr. Alan B. Colowick to Its Board of Directors
[September 22, 2015]

Dimension Therapeutics Elects Dr. Alan B. Colowick to Its Board of Directors


Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced the election of Alan B. Colowick, M.D., M.P.H., Executive Vice President of Celgene Corporation, to Dimension's Board of Directors (the "Board"). Dr. Colowick brings strong operational expertise and more than 15 years of experience in biopharmaceutical development. His election to the company's Board is effective immediately.

"Alan has a successful and highly regarded career in the life sciences, and we are pleased to welcome him to Dimension's Board," said Annalisa Jenkins, MBBS, MRCP, Chief Executive Officer of Dimension. "His track record in advancing products into the market and successfully commercializing them will be vital as we continue to progress our lead programs for rare, genetic diseases associated with the liver, including our wholly owned program in hemophilia B, which is anticipated to enter the clinic this year."

"Alan has built and managed highly regarded clinical teams capable of supporting multiple, simultaneous clinical trials on a global basis," stated Ben Auspitz, Partner, Fidelity Biosciences, and Chairman of Dimension's Board. "We expect we will benefit greatly from his insights and unique perspective addressing patient populations with substantial unmet needs."



Prior to his current role as Executive Vice President of Celgene Corporation, Dr. Colowick was Celgene's President of the Europe, Mid-East, and Africa region (EMEA), for which he was responsible for staff and operations in over 40 countries, and prior to that served as Senior Vice President, Global Medical Affairs. Previously, he was Chief Executive Officer of Gloucester Pharmaceuticals, LLC (acquired by Celgene in 2010), and prior to this, he was President, Oncology at Geron Corporation. He also served as Chief Medical Officer of Threshold Pharmaceuticals, and prior to this, Dr. Colowick held leadership positions of increasing responsibility at Amgen Inc., including as Vice President of European Medical Affairs. While at Amgen, Dr. Colowick led the team responsible for the successful registration and launch of Aranesp® in the US, EU, and Australia. He holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University, and an M.P.H. from Harvard University. Dr. Colowick also completed a clinical and research fellowship in hematology and oncology at the Dana Farber Cancer Institute and Brigham and Women's Hospital at Harvard University.

About Dimension Therapeutics


Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.

For more information please visit www.dimensiontx.com


[ Back To TMCnet.com's Homepage ]